Lentiviral vectors are being increasingly used as tools for stable integration of large gene inserts into the genomes of both dividing and non-dividing cells. With 3rd and 4th generation of lentiviral vectors being incompetent of replication, they also offer a relatively safe tool for more widespread use. Currently, lentiviral based therapies are primarily ex-vivo, such as CAR-T, however recent animal studies have successfully demonstrated their use in-vivo as well. To enable more widespread use, as well as development of in-vivo therapies in humans, better downstream processes for lentiviral purification are needed.
In this work, we present the results of lentiviral downstream optimisation on CIM® QA monolith with the use of DoE. Using DoE, we successfully increased infectious lentiviral recovery to 70%, a 3x increase, compared to initial results. Interestingly, salt concentration in loading sample was determined as the most important factor for high infectious recovery of lentivirus from CIM QA column.
